Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
135
resultados
Última actualización
09/10/2025 [12:59:00]
Resumen de: EP4628100A2
This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS-CoV-2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drugs formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations, that are incorporated into a pulmonary and oral delivery systems.
Resumen de: US2025304659A1
The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-1 and methods for use thereof.
Resumen de: WO2025202222A1
The present invention relates to the use of a STING agonist, of a TLR5 agonist or of a TLR7 agonist for enhancing the number of p16high immune cells in vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is also herein reported that p16high immune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. The present invention thus relates to a pharmaceutical composition comprising autologous or heterologous p16high immune cells such as p16high CAR-T cells, and its use for various therapeutic purposes. These cells are preferably obtained by contacting them with a STING agonist, a TLR5 agonist and/or a TLR7 agonist.
Resumen de: AU2024236771A1
The present invention relates to an in-vitro method for screening a subject, for determining the severity of Covid-19 outcome caused by Severe Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) using combination of gene signature comprising human RNA based biomarker and a kit thereof.
Resumen de: AU2024234831A1
In alternative embodiments, provided are pharmaceutical compositions and therapeutic combinations of drugs, including products of manufacture and kits, for treating, preventing or ameliorating (for example, decreasing the symptoms of, or decreasing the mortality of) a viral infection, for example, a coronavirus infection such as a COVID-19 or variant thereof, and methods for making and using same. In alternative embodiments, provided are products of manufacture and kits for delivering pharmaceutical compositions and therapeutic combinations of drugs as provided herein, for example provided are transdermal delivery devices such as patches that can have multiple compartments for delivering transdermally different drugs at the same time.
Resumen de: WO2025207791A1
Aspects are directed to a novel small molecule inhibitor of Nsp16 having a chemical formula of (N-9-(2R,3R,4S,5S)-5-(chloromethyl)-3,4-dihydroxy-tetrahydrofuran-2-ylpurin-6-ylprop-2-enamide) (AT501) or analogs thereof. Other aspects are directed to a therapeutic composition comprising AT501 or analogs thereof, further including antiviral compounds or anticancer compounds. Certain aspects are directed to a method of treating Coronavirus infection by administering AT501 or a composition thereof to a subject having or at risk of obtaining a Coronavirus infection caused by SARS-CoV-1 or SARS-CoV-2 virus. Certain aspects are directed to methods of treating cancer by administering AT501 or a composition thereof to a subject having or at risk of developing cancer, such as leukemia.
Resumen de: WO2025203062A1
The present invention relates to the preparation of indole-based compounds in free form or an acceptable salt form potential therapeutic target as an antiviral agent against SARS-Cov2. The indole-based small molecules are, capable of antiviral activity in RT-qPCR and cell-based assay in SARS-CoV-2 infected VERO E6 cells, that may ultimately be used to achieve improved human health in patients against covid- 19 or other similar viral diseases.
Resumen de: WO2025201575A2
Disclosed in the present invention are an anti-SARS-CoV-2 arylnaphthalene lignan compound, and a preparation method therefor and the use thereof. Results show that ANL-1, ANL-2, and ANL-4 to ANL-7 have no toxicity to Vero E6 cells, and ANL-3 has low toxicity to Vero E6 cells. In a Vero E6 cell model, the in vitro anti-SARS-CoV-2 activities of ANL-7 and ANL-2, in TI value, are respectively 19 times and 16 times that of remdesivir, and are higher than the in-vitro anti-SARS-CoV-2 activity of a market-available drug. ANL-2 has a significant inhibitory effect on RNA-dependent RdRp activity of SARS-CoV-2, and ANL-2 also effectively limits the replication of various pathogenic coronaviruses in Caco2 cells or hamsters. It can be seen that the arylnaphthalene lignan compound has a good anti-coronavirus activity and can be used for treating and preventing SARS-CoV-2 infection or delaying the progress of SARS-CoV-2 infection in a patient.
Resumen de: WO2025208143A1
Compositions and methods for treating a viral condition. The composition is administered to the subject in a therapeutic amount. The composition includes a first medicament effective for up-regulating disulfide bond donation and exchange, and a second medicament comprising a DNA polymerase inhibitor, a protease inhibitor, a DNA/RNA inhibitor, an intron splicer, or combinations thereof. The first medicament is effective for causing viruses to dissociate from integration sites and actively replicate with availability of disulfide bonds. The second medicament is effective for supporting or improving degradation, slicing, and/or inhibition of viral RNA, viral DNA, and/or viral proteins. The virus is Coronavirus, Epstein Barr virus, human papillomavirus, or herpes simplex virus.
Resumen de: US2025304972A1
Novel compounds capable of blocking viral infections sustained by the SARS-Cov2 virus are provided. A method for preventing and/or treating infectious diseases caused by a virus involving administering the novel compounds is also provided.
Resumen de: WO2025202219A1
The present invention relates to the use of Melanoma Differentiation-Associated protein (MDA5) inhibitors for enhancing the number of p16high immune cells in vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is moreover herein reported that p16high immune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. Mechanistically, it is shown that inhibition of MDA5 induces an increase in p16high immune cells subsets that, in turn, establishes a low adenosine environment and disease tolerance. The present invention also relates to a pharmaceutical composition comprising immune cells such as CAR-T cells in which the MDA5 expression and/or activity is inhibited, and its use for various therapeutic purposes.
Resumen de: US2025304996A1
The present invention relates to pseudotyped lentiviral vectors, particularly to pseudotyped with a modified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, as well as related constructs, methods and therapeutic indications.
Resumen de: US2025302944A1
COMBINATION OF EPITOPES AND USE THEREOF, VACCINE CONSTRUCT, METHOD OF INDUCING AN IMMUNE RESPONSE, METHOD FOR THE IDENTIFICATION OF EPITOPES The present invention refers to a combination of epitopes comprising at least eight T cell epitopes from the SARS-CoV-2, as well as the use of said combination (“set of epitopes”). Said epitopes are widely recognized by CD4+ T-lymphocytes of the overwhelming majority of COVID-19 convalescent individuals.
Resumen de: US2025304559A1
The invention relates to compounds of Formula Iand pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q′ and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
Resumen de: US2025306023A1
A method and system for predicting/diagnosing inflammatory diseases, such as, multisystem inflammatory syndrome in children (MIS-C), Kawasaki disease, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), respiratory syncytial virus, an adenovirus, influenza A, B C, or D, and/or parainfluenza in a subject is described.
Resumen de: US2025303337A1
An apparatus used with supplied power for treating air in an environment and method of use. A housing is mobile in the environment and has an intake and an exhaust. At least one prime mover is disposed in the housing and is operable to move the air in the environment through the housing from the intake to the exhaust. At least one permeable barrier is disposed in the housing and is configured to impede the moved air flow therethrough up to an impedance threshold. The permeable barrier is in electrical communication to the supplied power and is heated to a surface temperature.
Resumen de: EP4623909A1
The present invention relates to a pharmaceutical composition comprising a first active ingredient and a second active ingredient, wherein the first active ingredient is compound 1, an ester corresponding thereto, a salt corresponding thereto, a salt of the ester corresponding thereto, or a combination of the substances, and the second active ingredient is ATV014, or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof. The molar ratio of the first active ingredient to the second active ingredient is 50: 1-1:50. The composition has relatively good prospects for pharmaceutical development.
Resumen de: MX2025009166A
A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.
Resumen de: MX2025009564A
A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt% total catechins, at least 20 wt% total chlorogenic acids, and optionally up to 30 wt% total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.
Resumen de: EP4623924A1
Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of shortness of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.
Resumen de: KR20250142840A
본 개시 내용에 따르면, 코로나 바이러스와 같은 검출 대상 바이러스의 RNA가 포집 프로브(capture probe)인 금-DNA-양자점에 부착되어 DNA-RNA 부합체를 형성한 다음, 이중나선 특이적 핵산분해효소(Duplex-specific nuclease; DSN)에 의하여 DNA가 소화됨에 따라 포집 프로브로부터 양자점의 금속 이온이 방출되고, 이와 같이 방출된 양자점의 금속 이온을 센싱함으로써 시료 내 검출 대상 바이러스(구체적으로, 코로나 바이러스)를 정량적 및/또는 정성적으로 검출하는데 적합한 복합 전극 및 센서가 기재된다.
Resumen de: US12427177B1
The present invention relates to a composition and use thereof directed towards treating various health ailments, such as skin and respiratory problems and various infections. More particularly, the present invention relates to a lime sulfur solution and use thereof, of varying percentages, directed towards improving vision and treating various skin problems and infections, such as toenail fungus, athlete's foot, jock itch, skin psoriasis, eczema, vaginal yeast infections, head or beard dandruff, respiratory infections, itching of the skin (particularly of the hands), acne (facial and/or body acne), poison ivy, insect bites, head and body lice, crabs, cuts, treating wounds infected by staff and/or MRSA (methicillin-resistant Staphylococcus aureus) bacteria, tongue thrush, ringworm, penis foreskin infections, skin tags, and is also directed towards treating various respiratory infections (such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, and Covid-19 infections). The present invention also relates to use of the aforementioned composition and solution as a disinfectant in gyms, spas, saunas, for professional athletes, or as a body and/or hair wash.
Resumen de: US12427191B1
A SARS-CoV-2 immunotherapeutic targeted fusion protein regimen or vaccine in which the extracellular domain (ecd) of the CD40L immunostimulatory protein, is attached individually to mRNA encoding a Selected Fragment of the Spike Protein (SFSP), representing a different functional feature and a different domain or domain region, or both of the Spike Protein, to generate 7 distinct SFSP/ecdCD40L translation units, each translation unit being converted into a SFSP/ecdCD40L fusion protein regimen or vaccine and all combined into a single fusion protein mixture or composition for injection, preferably inter-muscularly (im). Each fragment or peptide is designed to activate a humoral and cellular immune response to a different SFSP. Each SFSP fragment or peptide, as a vaccine strategy for the SARS-CoV-2 virus, has the capability to suppress the emergence of immunological escape mutants. The fusion protein mixture or composition of multiple fragments or peptides could be incorporated in any one of several delivery platforms such as an adenoviral expression vector or an mRNA platform.
Resumen de: US2025297314A1
The invention relates to an in vitro or ex vivo method for determining the risk of death in a subject infected with a respiratory virus, for example SARS-CoV-2, comprising a measurement, in a biological sample of said subject, of the level of expression of the CD74 gene; the invention also relates to associated kits.
Nº publicación: US2025298008A1 25/09/2025
Solicitante:
CENTRE FOR IMMUNOLOGY & INFECTION LTD [HK]
Centre for Immunology & Infection Limited
Resumen de: US2025298008A1
The present invention uses ex vivo human airway cultures to assess the human transmissibility and replication competence of influenza and coronavirus strains. By comparing pandemic influenza A subtype H1N1 and highly pathogenic avian influenza H5N1 as reference strains, the transmissibility risk of various viruses was evaluated and categorized. Additionally, an in vitro model evaluated virus-induced impairment of alveolar fluid clearance (AFC) as an indicator of disease severity. The study revealed correlations between bronchus viral replication, human transmission, AFC impairment, and clinical disease severity across different influenza and coronavirus strains.
BOPI
Sede Electrónica
